You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 24, 2024

CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for cilastatin sodium; imipenem; relebactam and what is the scope of freedom to operate?

Cilastatin sodium; imipenem; relebactam is the generic ingredient in one branded drug marketed by Msd Merck Co and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Cilastatin sodium; imipenem; relebactam has seventy-one patent family members in thirty-eight countries.

One supplier is listed for this compound.

Summary for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
International Patents:71
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Clinical Trials: 2
DailyMed Link:CILASTATIN SODIUM; IMIPENEM; RELEBACTAM at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
Generic Entry Date for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM*:
Constraining patent/regulatory exclusivity:
Dosage:
POWDER;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
M.D. Anderson Cancer CenterPhase 2
Merck Sharp & Dohme Corp.Phase 3

See all CILASTATIN SODIUM; IMIPENEM; RELEBACTAM clinical trials

Pharmacology for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

US Patents and Regulatory Information for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Merck Co RECARBRIO cilastatin sodium; imipenem; relebactam POWDER;INTRAVENOUS 212819-001 Jul 16, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Msd Merck Co RECARBRIO cilastatin sodium; imipenem; relebactam POWDER;INTRAVENOUS 212819-001 Jul 16, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Msd Merck Co RECARBRIO cilastatin sodium; imipenem; relebactam POWDER;INTRAVENOUS 212819-001 Jul 16, 2019 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for CILASTATIN SODIUM; IMIPENEM; RELEBACTAM

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2666774 122020000036 Germany ⤷  Sign Up PRODUCT NAME: RELEBACTAM, ODER RELEBACTAM IN FORM DES MONOHYDRATES, IMIPENEM UND CILASTATIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1420 20200213
2231667 PA2020516 Lithuania ⤷  Sign Up PRODUCT NAME: RELEBAKTAMAS ARBA JO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/19/1420 20200213
2231667 C20200021 00336 Estonia ⤷  Sign Up PRODUCT NAME: RELEBAKTAAM;REG NO/DATE: EU/1/19/1420 17.02.2020
2666774 2020024 Norway ⤷  Sign Up PRODUCT NAME: KOMBINASJON AV RELEBAKTAM EVENTUELT I FORM AV MONOHYDRAT, IMIPENEM OG CILASTATIN, EVENTUELT I FORM AV NATRIUMSALT; REG. NO/DATE: EU/1/19/1420 20200219
2231667 30/2020 Austria ⤷  Sign Up PRODUCT NAME: RELEBACTAM ODER EIN MONOHYDRAT DAVON; REGISTRATION NO/DATE: EU/1/19/1420 (MITTEILUNG) 20200217
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.